Tarlatamab plus durvalumab cuts death risk 58% in first-line small cell lung cancer, extending median overall survival to ...
RELATIVITY-047's 5-year survival data and LAG-3-high CD8+ T cell biomarker findings signal a shift in how immuno-oncology ...
NHWD-870 HCl achieves 45% response rate in thoracic NUT carcinoma, nearly doubling the overall cohort's 30% rate in advanced ...
FDA AI Guidance requires clinical trial sponsors to validate algorithms before submission, shifting documentation and testing ...
ASP-1929 + Pembrolizumab achieved 28.2-month median OS in recurrent/metastatic HNSCC, with 35% alive at four years in Phase ...
Medpace wins the SCRS Eagle Award for CRO for the second consecutive year, based on ratings from nearly 2,000 global research sites.
Lilly's sofetabart mipitecan achieves 79% response rate in platinum-sensitive ovarian cancer patients, including those with prior PARP inhibitor exposure.
WCG's Activation Intelligence targets clinical trial rework by catching document conflicts before activation, saving sites ...
“Study builds [in TrialKit] went from anywhere from two to six weeks to one to three to four days. The work Floyd is doing on ...
A Nature Neuroscience study separates psilocybin's neuroplastic effects from its hallucinogenic ones, and it should reshape ...
MA beneficiaries received kidney transplants at nearly half the rate of traditional Medicare patients post-Cures Act, a ...
OD-001 Phase 2a ulcerative colitis study hits primary endpoint with 2.4-point modified Mayo score reduction at Week 12, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results